Here are 3 ASX healthcare share results you might have missed

Regis Healthcare, EBOS and Neuren Pharmaceuticals are three ASX healthcare shares that just posted results. Here is what you need to know.

| More on:
Three healthcare workers standing together and smiling.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) has been in a pendulum swing over the ASX reporting season. Here are three ASX healthcare companies that have gone under the radar.

Regis Healthcare Ltd (ASX: REG)

The Regis share price only lifted 0.32% to close at $1.59 after the company released its FY22 results today.

The ASX-listed residential care provider recorded a net loss after tax of $38.8 million. This is a major reversal of its net profit after tax (NPAT) of $19.9 million in FY21. It didn't help that revenue only grew 3.4%.

One reason for the drop in Regis' bottom line is likely the Australian government's 2021-22 budget decision to remove Aged Care Approval Rounds. This means from 1 July 2024, consumers can choose an approved provider that best suits their needs. Consequently, the government will discontinue operational places/bed licenses from this date.

Given this discontinuation, the depreciation of the operational places needs to be adjusted from an indefinite period to the date of expiry, being 1 July 2024. The change brought about a $61 million negative impact on net profit.

However, this does not affect cash flow as Regis still declared a final dividend of 2.32 cents per share.

The dividend is 50% franked and payable on 30 September.

EBOS Group Limited (ASX: EBO)

The EBOS share price only increased 1.59% to close at $34.54 per share on Wednesday despite a strong set of FY22 results.

EBOS is a wholesaler and distributor of healthcare, medical and pharmaceutical products.

Revenue surged 16.6% to a record high of $10.7 billion due to strong performances from both the healthcare and animal care segments. Net profit after tax also rose from $202.6 million in FY21 to $228.2 million.

The healthcare distributor also declared a final dividend of NZ 49 cents per share, resulting in total dividends declared for FY22 to NZ 96 cents per share.

Despite the inflationary environment, the adverse impact of supply chain issues, and staff shortage, EBOS still managed to increase earnings before interest and taxation margin slightly in FY22.

Management emphasised the resilience of the business and expect another year of profitable growth in FY23. They believe the balance sheet is in sound shape to support expenditure needs as well as future growth opportunities.

Neuren Pharmaceuticals Ltd (ASX: NEU)

The Neuren share price went down slightly by 2.14% to $5.48 at the close of trade today on the back of company results for HY22.

Total revenue moved slightly from $234,000 to $283,000. Neuren's net loss improved ever so slightly by 11% to $7 million.

Neuren is a biopharmaceutical company that engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. So, it's still spending money to develop commercial solutions.

The most notable development was in July when Neuren's US partner Acadia Pharmaceuticals submitted an application to the US Food and Drug Administration (FDA) for trofinetide, a drug that could treat Rett syndrome in adults and pediatric patients aged two years and older.

While an application is promising, it's still too early to know whether this will be a success or not. Such is the unpredictable nature of biotech companies.

Motley Fool contributor Raymond Jang has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Miner looking at a tablet.
Earnings Results

Rio Tinto share price on watch following FY 2023 earnings miss

Rio Tinto's iron ore operations were on form in 2023. It's a shame the rest of the business wasn't.

Read more »

Man with rocket wings which have flames coming out of them.
Earnings Results

4 All Ords ASX dividend shares going gangbusters on results

All Ords investors are sending these ASX dividend shares soaring on the back of their earnings results.

Read more »

Man waiting for his flight and looking at his phone.
Earnings Results

Corporate Travel share price plunges 18% despite tripling net profits

An explosion in earnings is taking a backseat to changes in Corporate Travel Management's full-year forecasts.

Read more »

happy woman throws arms in the air
Bank Shares

NAB shares hit 52-week high on first-quarter earnings beat

NAB appears on track to at least deliver on first-half expectations.

Read more »

A man wearing a shirt, tie and hard hat sits in an office and marks dates in his diary.
Earnings Results

Santos share price slips on 42% profit drop in FY23 result

Profits come back down to Earth in FY23.

Read more »

a man sits on a ridge high above a large city full of high rise buildings as though he is thinking, contemplating the vista below.
REITs

Here are 4 ASX 200 REITs results catching the eye on Wednesday

A mixed set of results have been announced by these property companies.

Read more »

Three analysts look at tech options on a wall screen
Earnings Results

WiseTech share price leaps 8% today as revenues surge

ASX 200 investors are bidding up the WiseTech share price today.

Read more »

Two parents and two children happily eat pizza in their kitchen as a top broker predicts a 46% upside for the Domino's share price
Earnings Results

Domino's share price charges higher on improving outlook

Here's how this struggling pizza chain operator performed during the first half.

Read more »